NEW YORK (GenomeWeb) – BGI Genomics and digital health startup Pryzm Health said today that they have agreed to share technology in pursuit of what they called "precision public health" for the Australian market.
The companies have signed a memorandum of understanding to "develop foundational capabilities to drive equitable access to precision medicine approaches across the health system," according to the announcement. They will pair genomics testing from BGI with the data genotype-phenotype matching and analytics technology of Pryzm in pursuit of greater access to precision health services, faster diagnoses, better patient outcomes, and lower costs, the partners said.
"One of the key limitations in realising the value of genomic data in both research and clinical practice is access to structured and high-quality phenotypic data. Pryzm’s core capabilities of acquiring and classifying clinical features and symptoms will meet a critical need for accelerating routine use of genomic data in healthcare settings," Tudor Groza, cofounder of Sydney, Australia-based Pryzm Health, said in a statement.
"Pryzm and BGI are a perfect match with our complementary skills in population-scale genome sequencing," added Ning Li, chief development officer of Shenzhen, China-based BGI Genomics. "We are thrilled to join forces with Pryzm and to explore the combined power of genomics and phenomics with Pryzm to improve patient outcomes and enhance public health."